Poxel SA (7PO) AI Stock Analysis

Poxel SA

(Frankfurt:7PO)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Commercial partnership with Sumitomo PharmaA revenue-generating, arm’s-length commercialization partnership in Japan provides durable non-dilutive cash via milestones/royalties and shifts commercialization burden to an established local partner. This reduces short-term capex needs and supports predictable collaboration receipts over coming quarters.

Negative Factors

Highly stressed balance sheetDeep negative equity combined with rising debt materially limits financial flexibility, increasing refinancing and dilution risk. Over a multi‑month horizon this constrains runway for R&D and commercialization investments and raises the probability management must seek costly external funding.

Poxel SA (7PO) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 11.01M
Dividend Yield: ―
Average Volume (3M): 12.55K
Price to Earnings (P/E): -0.4
Beta (1Y): -1.95
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 5
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Poxel SA Business Overview & Revenue Model

Company Description

Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Imeglimin, is a...

Poxel SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:7PO against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:MEDCL	50Neutral	EUR 948.13M	-28.97	―	―	-23.21%	-50.69%
FR:IVA	46Neutral	EUR 760.35M	-6.00	-1625.48%	―	-99.64%	68.67%
FR:GNFT	44Neutral	EUR 541.90M	-5.32	279.22%	―	27.70%	-162.89%
FR:ALGAE	43Neutral	EUR 46.73M	-4.49	-32.62%	―	3.22%	24.05%
FR:ALVAL	37Underperform	EUR 22.31M	-2.13	-87.66%	―	183.47%	57.15%

* Healthcare Sector Average

Performance Comparison

DE:7PO and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:7PO	Poxel SA	0.16	-0.14	-46.38%
FR:GNFT	Genfit SA	10.86	7.31	205.92%
FR:IVA	Inventiva SA	3.18	-0.34	-9.66%
FR:ALVAL	Valbiotis SA	0.63	-0.01	-0.95%
FR:ALGAE	Fermentalg SA	0.39	-0.09	-19.59%
FR:MEDCL	MedinCell SA	26.36	-10.42	-28.33%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Poxel SA AI Stock Analysis